Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain, sickle cell disease, beta thalassemia, and type 1 diabetes, with approved products in each area. Suzetrigine ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not enough over Hydrocodone + Acetaminophen. But….there’s more. What about ...

Vertex Pharmaceuticals Incorporated ... JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 ...

Vertex continues to capitalize on its leadership ... U.S. patients prescribed treatments for moderate-to-severe acute pain annually. The pill's arrival coincides with federal and state legislation ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Still, with a high-quality profile and positive momentum in pain and gene therapy, Fye believes Vertex could continue to benefit from rotation in this macro backdrop. JPMorgan reiterated its ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...